COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION

• US 20170342068A1
• Filed: 05/16/2017
• Published: 11/30/2017
• Est. Priority Date: 05/27/2016
• Status: Active Grant

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: Aktoudianakis, Evangelos, Canales, Eda, Chin, Elbert, Currie, Kevin S., Katana, Ashley Anne, Kato, Darryl, Link, John O., Metobo, Samuel E., Saito, Roland D., Yang, Zheng-Yu
• Granted Patent: US 10,100,052 B2
• Time in Patent Office: Days
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

Claims

1-11. -11. (canceled)

12. A compound selected from the group consisting of:

14. The compound of claim 12 having the formula:

15. The compound of claim 12 having the formula:

18. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt of claim 12, and a pharmaceutically acceptable excipient.

19. A method of inhibiting the production and/or secretion of HBsAg in an individual infected with HBV comprising administering a therapeutically effective amount of a compound or pharmaceutically acceptable salt of claim 12 to the individual.

20. A method of treating or preventing an HBV infection comprising administering to an individual in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt of claim 12 to the individual.

13. A compound selected from the group consisting of:

16. The compound of claim 13 having the formula:

17. The compound of claim 13 having the formula: